Literature DB >> 2525950

Modification of host antitumor defense mechanisms in mice by progressively growing tumor.

D L Maccubbin1, K F Mace, M J Ehrke, E Mihich.   

Abstract

The EL4 lymphoma in C57BL/6 mice was used as a model to examine the effect of progressive tumor growth on a variety of cell mediated cytolytic effector functions which have been shown in other systems to have antitumor potential. The functions examined were those of cytolytic T-lymphocyte, lymphokine activated killer cells, natural killer cells, and tumoricidal macrophage (MO). The kinetics of each function displayed a unique pattern as a consequence of tumor growth, but all were inhibited in animals bearing large tumors (late tumor bearers). In cell mixing experiments it was shown that spleen cells from individual late tumor bearers were suppressive for cytotoxic T-lymphocytes, lymphokine activated killer cells, and splenic MO but not peritoneal MO or splenic natural killer cells. The suppression was nonspecific and was mediated primarily by nonadherent cells and/or their soluble products. Suppression appeared to be mediated, in part, by tumor cells in the spleen since the degree of suppressor activity associated with a particular spleen cell preparation correlated with the number of tumor cells present. Furthermore, the direct addition of viable ascites EL4 cells to response cultures or assays had similar suppressive effects as late TBM spleen cells, i.e., inhibited cytotoxic T-lymphocytes, lymphokine activated killer cells, and splenic MO but had no effect on natural killer cells or peritoneal MO. The mechanism of suppression by ascites EL4 was not determined but it was mediated by viable cells only and not due to contaminating viruses or other microorganisms.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2525950

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  [Role of the spleen in tumor surgery].

Authors:  U Wolters; H W Keller; H Pichlmaier
Journal:  Langenbecks Arch Chir       Date:  1991

2.  A lack of evidence for down-modulation of CD3 zeta expression in colorectal carcinoma and pregnancy using multiple detection methods.

Authors:  A M Deakin; K Singh; J S Crowe; J H Ellis; A Dalgleish; R J Leicester; C J Finlayson; W F Miles; P F Life
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

3.  Immunosuppression in murine renal cell carcinoma. I. Characterization of extent, severity and sources.

Authors:  S K Gregorian; J R Battisto
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Mechanisms of tumor-induced immunosuppression: evidence for contact-dependent T cell suppression by monocytes.

Authors:  M L Jaffe; H Arai; G J Nabel
Journal:  Mol Med       Date:  1996-11       Impact factor: 6.354

5.  Preclinical evaluation of linear HPMA-doxorubicin conjugates with pH-sensitive drug release: efficacy, safety, and immunomodulating activity in murine model.

Authors:  Milada Sirova; Tomas Mrkvan; Tomas Etrych; Petr Chytil; Pavel Rossmann; Marketa Ibrahimova; Lubomir Kovar; Karel Ulbrich; Blanka Rihova
Journal:  Pharm Res       Date:  2009-11-06       Impact factor: 4.200

6.  Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor alpha combination treatment of EL4-lymphoma-bearing C57BL/6 mice.

Authors:  C M Krawczyk; S Verstovsek; P Ujházy; D Maccubbin; M J Ehrke
Journal:  Cancer Immunol Immunother       Date:  1995-06       Impact factor: 6.968

7.  An evolutionary perspective on anti-tumor immunity.

Authors:  David J Klinke
Journal:  Front Oncol       Date:  2013-01-10       Impact factor: 6.244

8.  Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.

Authors:  L Chen; P McGowan; S Ashe; J Johnston; Y Li; I Hellström; K E Hellström
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

9.  Improvement of macrophage dysfunction by administration of anti-transforming growth factor-beta antibody in EL4-bearing hosts.

Authors:  H Maeda; S Tsuru; A Shiraishi
Journal:  Jpn J Cancer Res       Date:  1994-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.